Avexa advisor starts pipeline 'value' review; Actavis wins an FDA approval;

 @FierceBiotech: Helicos slaps PacBio with patent lawsuit. Article | Follow @FierceBiotech

 @JohnCFierce: Interesting that it's the Japanese pharma companies jumping on board these obesity deals. | Follow @JohnCFierce

> Australia's Avexa says it has hired an advisor to take a hard look at its drug development assets and get back to the board with a plan for them. "We expect the review will provide the company with a clear picture of the potential value within Avexa's portfolio of assets," Avexa chairman Joe Baini said in a statement. Report

> The FDA has approved Actavis' app to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder. Actavis release

> Hong Kong-based Sinobiomed has named George Yu as its new CEO. Sinobiomed release

> Twin Cities-based Kip Biotech says that it has raised $1 million for its virtual business. Story

Special Report: Top 10 Women in Biotech

And Finally... Researchers at Boston University and the Wyss Institute for Biologically Inspired Engineering at Harvard have discovered that "charitable" behavior exists in one of the most microscopic forms of life--bacteria. Release

Suggested Articles

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.